306 results on '"Lemoli, R. M."'
Search Results
2. Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma
3. P539: PROGNOSTIC RELEVANCE OF MINIMAL RESIDUAL DISEASE IN THERAPY RELATED AND SECONDARY ACUTE MYELOID LEUKEMIA RECEIVING CPX-351 OR FLUDARABINE-BASED INDUCTION.
4. P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
5. P932: ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY
6. P529: FIRST EUROPEAN REAL-WORLD EVIDENCE PROSPECTIVE REGISTRY OF FIRST-LINE ADULT PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM TREATED WITH FIRST-IN-CLASS CD123-TARGETED THERAPY TAGRAXOFUSP
7. P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB
8. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia
9. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
10. Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of flt3-itd in npm1 mutated aml, irrespectively of flt3-itd allelic Burden
11. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization
12. Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA
13. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF
14. BU/melphalan and auto-SCT in AML patients in first CR: a ‘Gruppo Italiano Trapianto di Midollo Osseo (GITMO)’ retrospective study
15. Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia
16. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF
17. Phase I-II trial of adoptive immunotherapy with haploidentical KIR ligand-mismatched natural killer cells in high-risk acute myeloblastic leukaemia patients: O400
18. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase
19. Stem cell mobilization and collection in patients with liver cirrhosis
20. T lymphocyte killing by a xanthine-oxidase-containing immunotoxin
21. Sensitivity of chronic myeloid leukemia hemopoietic progenitors to PTT-119 in combination with human recombinant interferon alpha and gamma
22. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients
23. PB2097 METABOLIC STARVATION TRIGGERED BY L-ASPARAGINASE SENSITIZES MULTIPLE MYELOMA CELLS TO PROTEASOME INHIBITORS BY INDUCING DNA DAMAGE ACCUMULATION
24. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma
25. Sensitivity of Ph1+ CFU-GM to human recombinant interferon α and γ alone and in combination
26. Proteomic signature of CD34+ progenitors from chronic-phase chronic myeloid leukemia
27. CD133+ stem cells for the treatment of end-stage liver disease
28. Mobilization with chemotherapy+G-CSF+Plerixafor in Europe: The Italian Experience
29. Cell therapy: achievements and perspectives
30. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
31. CD34+ from high Sokal risk chronic myeloid leukaemia patients expresses gene profi le signifi cantly different from CD34+ obtained from low and intermediate Sokal risk pts: a subgroup of CML pts candidate to upfront search for BMT donor?
32. Hematopoietic stem cell mobilization in patients undergoing liver transplant or liver resection
33. Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas
34. Targeting the minimal residual disease in acute myeloid leukemia: the role of alloreactive natural killer cells
35. The therapeutic role of dendritic cells in cancer immunotherapy
36. Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients
37. Biological characterization of CD34+ cells mobilized into peripheral blood
38. Ex vivo expansion of hematopoietic cells and their clinical use
39. Allogeneic hematopoietic stem cells from sources other than bone marrow: biological and technical aspects
40. Fisiologia delle cellule emopoietiche e fattori di regolazione della proliferazione delle cellule emopoietiche
41. Peripheral blood stem cell transplantation for the treatment of multiple myeloma: biological and clinical implications
42. Peripheral blood CD 34+ from healthy donors mobilized by recombinant human granulocyte colony-stimulating factor for allogeneic transplantation, show the same frequency of colony-forming unit cells (CFU-C) and long-term culture initiating cells (LTC-IC) of bone marrow CD 34+ cells. Whereas they differ in cell-cycle distribution, apoptosis and in-vitro responsiveness to colony-stimulating factors
43. Human responses against HER-2-positive cancer cells in human immune system-engrafted mice
44. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation
45. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization
46. Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia
47. Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA
48. Positive selection of hematopoietic CD34+ stem cells provides 'indirect purging' of CD34- lymphoid cells and the purging efficiency is increased by anti-CD2 and anti-CD30 immunotoxins
49. Combination of hematopoietic growth factors containing IL-3 induce Acute Myeloid Leukemia Cell Sensitization to cycle specific and cycle non-specific drugs
50. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.